NHRA has updated three key pharmaceutical regulatory guidelines in Bahrain as part of its continuous regulatory updates during February 2026, including:

Medicine Licensing Guideline (Version 4.2)
Medicine Renewal Guideline (Version 2.2)
Medicine Variations Guideline (Version 3.2)

🔍 What’s new:

These updated documents provide clear instruction on the NHRA procedure for the New, Renewal &Variations of a Marketing Authorization Product (MA).

The latest revisions introduce updated related to assessment timelines and registration pathways.

💡 Key Points:

1️⃣ Medicine Licensing Guideline – Version 4.2 Key Updates:

• Addition of: Fast Track Pathway & Normal Registration Pathway
• Assessment duration updated to be 3 Working days for Fats Track and 35 Working days for Normal Pathways.
• Deletion of Annex III: New Medicine Checklist
• Deletion of Annex V: Hospital Pack Size Registration FAQ

2️⃣ Medicine Renewal Guideline – Version 2.2 Key Updates:

• Renewal application assessment timeline reduced from 30 working days → 25 working days

3️⃣ Medicine Variations Guideline – Version 3.2

• Variation applications are now clearly divided into:
  • Type IA Minor Variations
  • Type IB & Major Variations
• Updated assessment timelines:
  • Type IA Minor Variations:
    • Expected completion within 7 working days
  • Type IB & Major Variations:
    • Expected completion within 40 working days

📌 How ReguLinked Can Support

ReguLinked supports companies with:

• NHRA submission strategy (Fast Track & Regular Pathway)
• eCTD dossier readiness
• Variation classification
• Renewal compliance planning
• Lifecycle management strategy

📎 Official Guides:

• Medicine Licensing Guideline Version 4.2
• Medicine Renewal Guideline Version 2.2
• Medicine Variations Guideline Version 3.2

📨 Let Regulinked support your regulatory readiness with a fully compliant NHRA-aligned strategy.

“Book your complimentary consultation today”

📧 bd@regulinked.com 🌐 www.regulinked.com

#ReguLinked #NHRA #Bahrain #RegulatoryUpdate #MedicineRenewal #MedicineVariation #MedicineRegistration #MarketAccess #RegulatoryAffairs